Marie Bosslett, Assistant Editor

The phase 2a trial demonstrated the systemic treatment’s tolerable safety profile for patients with chronic and progressive hair loss.

A pilot study monitored the disease management, technical challenges, and overall benefits for chronic spontaneous urticaria.

The nonsteroid 1% cream treatment demonstrated good response and tolerability in patients with PPP.

The trial results indicated improved disease control, integrity of skin barrier, and minimal reactions for patients with rosacea.

This review of the latest dermatologic studies includes discussions on the relationship between atopic dermatitis and prurigo nodularis, the use of upadacitinib for treating PN, and more.

The clinical trial showed promising results for patients who used probiotics as an accompanying treatment.

This review of the latest dermatologic studies includes discussions on the development of the Hand Eczema Impact Scale, the role of tofacitinib on Th1 and Th2 cytokines, and more.

The late-breaking data will be presented at ACAAI’s annual Scientific Meeting.

Survey results presented at ACAAI’s annual Scientific Meeting demonstrate the limited influence of elimination diets for reducing symptoms of AD.

Click here to answer today’s poll and read more about the perception of telehealth treatment in dermatology.

The multicenter trial reported high response rates and low risk of discontinuation for treating long-term chronic inducible urticaria.

With this combined administration, patients saw noticeable and lasting improvements in severe cases of AD.

Results from Society for Melanoma Research Congress demonstrated excellent predictive power of noninvasive CP-GEP Merlin test.

Although further research is still needed, dermatologists and patients are generally satisfied with teledermatology treatment.

This new indication adds to existing clearance of a non-drug treatment for mild to severe inflammatory acne vulgaris.

ALPHA compared alitretinoin and phototherapy for speed and efficacy when treating chronic hand eczema.

Investigators noted that further research is needed to monitor the prevalence of cardiovascular disease in patients with vitiligo.

The novel drug demonstrated tolerability for AK treatment when applied to a field of 100 cm2 of the face or scalp.

The IL-17 inhibitor demonstrated biologic-level efficacy in moderate to severe plaque psoriasis.